沙美特罗氟替卡松对支气管哮喘患者血清IL-21和IgE水平的影响  

Influence of salmeterol fluticasone on serum IL-21 and IgE in the treatment of patients with bronchial asthma

作　　者：舒海燕[1] 

机构地区：[1]池洲市石台县人民医院内一科,安徽池州245100

出　　处：《临床肺科杂志》2015年第6期1114-1117,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨沙美特罗氟替卡松用于支气管哮喘治疗时对患者血清IL-21和Ig E水平的影响。方法采用沙美特罗氟替卡松吸入治疗78例支气管哮喘患者,同时选取45例健康体检人员作为对照组,分别检测支气管哮喘患者治疗前后及对照组人员血清IL-21及Ig E,并进行对比分析。结果 78例支气管哮喘患者总有效率为89.7%(70/78);支气管哮喘组血清IL-21及Ig E水平显著高于对照组(P<0.01);治疗3个月后支气管哮喘组血清IL-21及Ig E显著降低(P<0.01),但仍显著高于对照组(P<0.01)。结论沙美特罗氟替卡松吸入治疗支气管哮喘能够有效降低血清IL-21及Ig E水平,减轻气道炎症反应,进而降低气道高反应性,疗效可靠。Objective To discuss the influence of salmeterol fluticasone on serum IL-21 and IgE in the treatment of patients with bronchial asthma. Methods 78 patients with bronchial asthma were treated with salmeterol fluticasone, and the levels of serum IL-21 and IgE were detected and compared before and after the treatment with 45 healthy controls. Results The effective rate was 89. 7% in the study group. The levels of serum IL-21 and IgE were significantly higher in the study group than in the control group before the treatment （P〈0. 01）, and they decreased significantly in the study group after the treatment （ P 〈0. 01 ） , still higher than those in the control group （ P 〈0. 01）. Conclusion Salmeterol fluticasone can reduce the levels of serum IL-21 and IgE in the treatment of patients with bronchial asthma, alleviate the airway inflammatory reaction, and reduce airway hyperreactivity in the treatment of patients with bronchial asthma.

关 键 词：沙美特罗氟替卡松 支气管哮喘 IL-21 IGE 

分 类 号：R562.25[医药卫生—呼吸系统]